The phenomenon was explored on a molecular level: when exposed to cisplatin, cancer cells balance available NAD+ between PARP-1 (PARP-1 activity is needed for DNA repair) and PHGDH in favor of the repairing mechanism mediated by PARP1 and, instead of activating SSP, take serine from the medium. Here, PHGDH is linked to cancer.